Brian Goff - 01 Mar 2024 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role
Chief Executive Officer, Director
Signature
/s/ William Cook, as Attorney in Fact for Brian Goff
Issuer symbol
AGIO
Transactions as of
01 Mar 2024
Net transactions value
-$135,361
Form type
4
Filing time
05 Mar 2024, 16:10:31 UTC
Previous filing
24 Jan 2024
Next filing
07 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGIO Common stock Options Exercise $0 +8,500 +17% $0.000000 57,936 01 Mar 2024 Direct
transaction AGIO Common stock Sale $135,361 -4,156 -7.2% $32.57 53,780 05 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGIO Restricted stock units Award $0 +54,000 $0.000000 54,000 01 Mar 2024 Common stock 54,000 Direct F2, F3
transaction AGIO Stock options (right to buy) Award $0 +195,500 $0.000000 195,500 01 Mar 2024 Common stock 195,500 $32.27 Direct F4
transaction AGIO Restricted stock units Options Exercise $0 -8,500 -33% $0.000000 17,000 01 Mar 2024 Common stock 8,500 Direct F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold to cover the tax withholding obligation in respect of vesting of the reporting person's performance share units. This transaction was effected pursuant to durable automatic sale instructions consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act. Such instructions were included in the reporting person's restricted stock unit agreement dated March 1, 2023.
F2 Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F3 The restricted stock units were granted on March 1, 2024. Beginning on March 1, 2025, the shares underlying the restricted stock units will vest in three equal annual installments.
F4 This option was granted on March 1, 2024. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2025, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F5 The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.